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Background: To our knowledge no data exists comparing new generation commercially
available devices for transfemoral (TF) transcatheter aortic valve implantation (TAVI).
Methods: All consecutive patients from our single-center prospective registry with AS
treated with TAVI with from Edwards SAPIEN XT™ (SXT) vs. Medtronic CoreValve®
with AccuTrak™ delivery sy stem (MCVAT) when the devices became commercially
available were included. The study endpoints were according to the Valve Academic
Research Consortium (VARC) definitions.
Results: In total, 235 patients treated in our center by TF TAVI for severe AS were
included: 142 (60.4%) underwent SXT vs. 93 (39.6%) MCVAT. More females (60.6%
vs. 43.0%; p0.008) and smaller annulus size (23.21.9 vs. 24.32.0; p0.001) were
present in the SXT group. There were no differences between valves in 30-day combined
safety endpoint (SXT 26.1% vs. MCVAT 29.7%; p0.558), all-cause mortality (3.1% vs.
6.5%; p0.218), cardiovascular mortality (2.3% vs. 5.4%; p0.214), myocardial infarc-
tion (1.4% vs. 2.2%; p0.683) or stroke (0.7% vs. 1.1%; p0.774). Additionally, no
differences were observed in life-threatening bleeding (12.4% vs. 20.4%; p0.100) or
major vascular complications (12.0% vs. 9.7%; p0.583). Conversely, with SXT there
was a lower occurrence of conduction disturbances/arrhythmia (16.5% vs. 36.6%;
p0.001) and pacemaker implantation (5.8% vs. 33.3%; p0.001). Of note, a higher
device success (96.5% vs. 88.2%; p0.013) was observed with SXT. At median
follow-up of 328 (IQR 83-401) days, there was no difference in combined efficacy
endpoint (14.8% vs. 9.8%; p0.265) or mortality (8.0% vs. 6.5%; p0.654).
Conclusions: In our single center experience, there was a lower incidence of arrhythmia
and pacemaker, with higher device success with SXT. Differences in the characteristics of
the patients treated with each valve may explain some of these findings.
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Background: Previous studies showed that patients with impaired left ventricular (LV)
function and low-flow, low-gradient (LFLG) aortic stenosis (AS) are associated with high
operative risk and poor long-term outcome after surgical aortic valve replacement. The
aim of this study was to investigate the clinical outcome of LFLG AS after transcatheter
aortic valve implantation (TAVI).
Methods: 450 consecutive patients in high operative risk underwent TAVI with the
Medtronic Corevalve (Medtronic, Minneapolis, MN, USA) or Edwards Sapien (Edwards
Lifesience, Irvine, CA, USA) prostheses at our institution between June 2008 and
February 2012. Full data of 341 patients was collected. Of these, 190 patients presented
with normal-flow, high gradient (NFHG) AS (aortic surface area (ASA) 1.0 cm2, mean
gradient (Pmean)  30 mmHg, LV ejection fraction (LVEF)  50%) and 26 patients
with LFLG AS (ASA  1.0 cm2, Pmean  30 mmHg, LVEF  30%). Clinical
follow-up, echocardiography and measurements of NT-pro-BNP levels were analyzed at
10 days, 4 weeks, 6 month and 1 year after TAVI.
Results: Patients with LFLG AS had a higher all-cause mortality at 12 month after TAVI
compared to patients with NFHG AS (41% vs. 86%, p 0.0001). Nevertheless, surviving
patients with LFLG AS showed a significant and steady rise in LVEF after 4 weeks
(before 25.8  4.4% vs. 30 days 37.3  13.5%, p  0.05), after 6 month (39.1  12%)
and 1 year (51.7  4.6%) and a reduction of NT-pro-BNP (before 11956  8094 ng/L
vs. 12 month 1832  1261 ng/L, pn.s.). Furthermore, these patients showed reduced
symptoms of heart failure resulting in an improved NYHA functional class (LFLG vs.
NFHG: 4 weeks:1.1 0.8 vs.1.2 0.8; pn.s.; 6 month:1.4 0.5 vs.1.3
0.8; pn.s.; 12 month: 1.7  0.5 vs. 1.2  0.8; pn.s.).
Conclusions: This study shows that the all-cause mortality, 12 month after TAVI in
patients with LFLG AS is notably high. However, surviving patients presented an
enormous improvement in myocardial function and a high clinical benefit.
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Background: Previous studies showed that the paradoxical low-flow, low-gradient
(PLFLG) aortic stenosis (AS) is a highly challenging condition in terms of diagnostics and
therapy. Moreover, this subgroup demonstrates an increased all-cause mortality if treated
medically compared to surgically treated patients. The aim of this study was to investigate
the clinical outcome and mortality in patients with PLFLG AS after transcatheter aortic
valve implantation (TAVI).
Methods: 450 consecutive patients in high operative risk underwent TAVI with the
Medtronic Corevalve (Medtronic, Minneapolis, MN, USA) or Edwards Sapien (Edwards
Lifesience, Irvine, CA, USA) prostheses at our institution between June 2008 and
February 2012. Full data of 341 patients was collected. Of these, 190 patients presented
with normal-flow, high gradient (NFHG) AS (aortic surface area (ASA) 1.0 cm2, mean
gradient (Pmean) 30 mmHg, left ventricular ejection fraction (LVEF) 50%) and 28
patients with PLFLG AS (ASA 1.0 cm2, Pmean 30 mmHg, LVEF 50%, stroke
volume index (SVI)  35 ml/m2). Clinical follow-up, echocardiography and measure-
ments of NT-pro-BNP levels were analyzed at 10 days, 4 weeks, 6 month and 1 year after
TAVI.
Results: Patients with PLFLG AS had a similiar all-cause mortality at 12 month after
TAVI compared to patients with NFHG AS (85% vs. 85.6%, p0.771). The LVEF
decreased slightly but significant after 4 weeks (before 60.1  1.9% vs. 4 weeks 57.5 
5.5%, p0.049), but remained stable after 6 month (57.6  5.1%) and 1 year (56.9 
5.7%). Furthermore, patients with PLFLG AS showed slightly high values of NT-pro-
BNP at baseline but a similar reduction over time (PLFLG: before 3845 2966 ng/L vs.
1 year 2260 1814 ng/L, p0.079) in conjunction to reduced symptoms of heart failure.
NYHA functional capacity improved similar between both groups (PLFLG vs. NFHG:
4 weeks: 1  0.7 vs. 1.2  0.8; pn.s.; 6 month: 0.9  0.7 vs. 1.3  0.8;
pn.s.; 12 month: 1.3  1 vs. 1.2  0.8; pn.s.).
Conclusions: This study shows that patients with PLFLG AS have a similar benefit after
TAVI as patients with NFHG AS and should no longer be withheld from TAVI
procedures.
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Background: Transcatheter aortic valve implantation into failing aortic xenografts is
increasingly accepted as a new treatment option for patients in need of re-do open heart
surgery. Aim of the study was to compare the acute transvalvular hemodynamics between
the Medtronic Corevalve (MCV) prosthesis and the Edwards SAPIEN-valve (ESV) after
valve-in-valve implantation (ViVI).
Methods: A total of 24 pts (70.8% male, aged 72.66.7 years, mean logES
32.219.4%) underwent a transfemoral transcatheter ViVI for a failing aortic xenograft
at our institution. Due to the high frequency of small surgical valves (outer diameter - OD -
21mm: n11; 23mm n8; 25mm n2; 27mm n3) ViVI was predominantly done
with the MCV (17pts; 71%) compared to ESV (7pts; 29%: Edwards Sapien n2,
Sapien XT n5).
Results: Procedural success rate was 87.5%, with 1 pt. displaying moderate aortic
regurgitation (deep implanted MCV) and 2 pts. in need of a second MCV due to valve
embolisation into the ascending aorta (after attempting a high implantation within small
surgical xenografts, both with an OD of 21mm). Thirty-day-mortality was 0%. The
average mean aortic valve gradient (dPmean) decreased significantly after ViVI (30.614
vs. 14.36.1 mmHg). Acute hemodynamic data was significantly superior with MCV
implanted into xenografts with an OD 23mm (MCV n13: dPmean 12.03.9 mmHg;
ESV n3: dPmean 25.62.51 mmHg, p0.02) and severe patient prosthesis mismatch
was more likely with ESV (indexed effective orifice area: 0.640.19 vs. 0.860.16,
p0.04). The significantly higher gradient with ESV vs. MCV after ViVI into xenografts
with an OD of 23mm was confirmed by comparison of pooled and recently published
data of n64 ESV (Pmean 17.88.4 mmHg; p0.009).
Conclusions: The low 30d mortality suggests that percutaneous transcatheter ViV-
procedures for failing bioprosthetical aortic valves is an effective treatment option for
high-risk surgical patients. The MCV should be considered as the first choice in small
surgical xenografts (OD  23mm) due to lower remaining transvalvular gradients.
Nevertheless, the more demanding implantation with MCV indicates that a smaller
MCV-prosthesis (i.e. 23mm) is urgently needed to increase the safety of ViVI.
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Background: Scarcity of data is available regarding adequate choice of the postdilatation
balloon size in TAVI. Hereby, we demonstrate the value of CT scan to choose accurately
the post dilatation balloon size.
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Methods: From November 2007 to December 2011, 384 patients underwent TAVI in our
center [233 Edwards and 151 CoreValve]. 74 were treated with post dilatation for residual
AR following valve implantation. In this study, 68 were analyzed after excluding 6
patients due to unavailable data.
Results: Mean age was 796.2 yrs. Male gender was 42 (61.7%). Mean logistic
Euroscore and STS score were 25.217.3 and 9.19.1, respectively. Mean grades of
aortic regurgitation at baseline, before and after post dilatation were 1.31.1, 2.30.7 and
0.80.6, respectively. CT scan analysis showed annular coronal diameter 262mm,
sagittal diameter 223mm, mid-sinusal diameter 364mm, sinus-tubular junction
275mm, annular eccentricity index 0.90.1. Mean number of calcified commisures
1.9 1.1, mean number of annular calcium spots 2.31.2. Edwards valve was used in 13
(19.1%), while CoreValve in 55 (80.8%). Mean valve size was 27.12.2 mm. Mean
balloon size was 25.62.3mm. Postdilatation was effective in reducing AR by 1 grade in
42 patients (79%). Effective post dilatation was achieved in 100% of patients with a “post
dilatation balloon diameter/ coronal diameter ratio” 0.85-1.07. Outcome of post dilatation
was not influenced by the annular eccentricity index. AR following postdilatation was
more in patients with heavily calcified annulus. 1 patient (1.5%) had annular tear
following post dilatation. 30 days echocardiographic follow up showed 1.10.9 AR.
Conclusions: Effectiveness of post dilatation is multifactorial and depends mainly on the
proper choice of the balloon size, which in terms depends on the annular coronal diameter
assessed by CT scan. Since commisural calcification and annular eccentricity index don’t
influence the outcome of post dilatation, there is no need for aggressive postdilatation to
reduce AR after valve implantation.
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Background: There is accumulating evidence that up to 20 % of the implanted devices
after TAVI are associated with a significant degree of paravalvular leaks (PVL), but the
clinical impact of PVL is still insufficiently explored.
Methods: A total of 355 patients with severe aortic valvulare stenosis (AVS) were treated
by TAVI (Corevalve n 222, Edwards Sapien n 133). Survival, NT-pro-BNP and the
grade of PVL were quantified up to 12 months after implantation.
Results: Technical success rate was 97 %. Thirty-day mortality was 9.6%. Post-
procedural transvalvular aortic regurgitation was seen only in a minority of cases (5%),
whereas PVL were frequently observed (grade:1	 in 58.2%, 1	2	 in 33.9%,
and 2	 in 7.9%). There was a clear relation-ship between PVL and adverse outcome
(p 0.001). After a transient increase NT-pro-BNP showed a significant decline.
Interestingly, a PVL 2	 was associated with a much higher rise in NT-pro-BNP
compared to the other groups (p 0.01), and a post-procedural increase in NT-pro-BNP
by more than 1640ng/L was associated with a significant increase in rate of death
(p 0.01).
Conclusions: TAVI is an efficient treatment option for high-risk patients with severe
AVS. The incidence of PVL is an inacceptable clinical problem and still insufficiently
recognized. Serial measurement of NT-pro-BNP can be used for risk-stratification in
patients with a significant PVL. In general, PVL graded 2	 is associated with a
dramatically increased 6-month mortality. Therefore, any action to fight against parapros-
thetical regurgitation is highly recommended.
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Background: The logistic European System for Cardiac Operative Risk Evaluation
(logEuroSCORE II) has been introduced to improve prediction of acute mortality in
cardiac surgery. No specific tools exist for evaluation of patients undergoing transcatheter
aortic valve implantation (TAVI). We assessed predictive ability of the logEuroSCORE
II for perioperative mortality after TAVI and compared it to four other systems of
preoperative risk evaluation.
Methods: 300 consecutive patients (age80.77.2years,59.5%female) undergoing TAVI
using Edwards Sapien (XT) devices were entered into a prospective dedicated database.
Preoperative risk stratification was performed using logEuroSCOREs I and II, Society of
Thoracic Surgeons (STS), Ambler and Parsonnet Scores. Validity of scores was assessed
by receiver-operator curves (ROC) and resulting area under the curve (AUC).
Results: Observed 30-day mortality in our sample was 10.7%(32/300). Calculated scores
were: logEuroSCORE I mean22.8%,CI0.21-0.246, logEuroSCORE II mean 7.3%, CI0.064-
0.081, STS mean 8.6%, CI0.077-0.095, Ambler mean 6.3%, CI0.057-0.070, Parsonnet mean
22.5%, CI0.209-0.241. ROC analyses revealed none of the tested systems to possess adequate
predictive value for acute mortality following TAVI: logEuroSCORE I AUC0.57, CI0.45-
0.69, logEuroSCORE II AUC0.58, CI0.47-0.70, STS AUC0.59, CI0.47-0.71, Ambler
AUC0.53, CI0.41-0.65, Parsonnet AUC0.51, CI0.38-0.64. To estimate accuracy (sum of
correct positive and negative predictions), Youden-indices (maximum of sensitivity and
specificity) were calculated and used to determine thresholds for classification of scores as
false/true. Derived accuracy was low, ranging between 34.0%(Ambler) and 55.2%(logEuro-
SCORE II).
Conclusions: None of the tested risk stratification systems including the new logEuro-
SCORE II provided adequate prediction of acute mortality in our large routine TAVI
cohort. Likely, scoring systems derived from classic cardiac surgery databases are
inadequate for risk prediction in TAVI patients. Therefore, specific risk models are needed
for high-risk patients undergoing TAVI. Until these are available, evalutation of
perioperative risk has to rely on interdisciplinary clinical judgment of individual patient
factors.
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Background: Transcatheter valve-in-valve implantation (VinV-TAVI) has emerged as a
potential option in addition to reoperative surgical aortic valve replacement to treat failed
biological heart valve substitutes, however with limited experience. Herein we report the
comprehensive experience of VinV-TAVI in the Nordic countries from May 2008 to
January 2012.
Methods: A total of 49 VinV-TAVIs (45 aortic, 2 mitral and 2 tricuspid) were performed
during this time period in 11 centers. For the aortic VinV:s, the mean age of patients was
80.6 (61-91) years (M 26;F 19) and mean Euroscore, Euroscore II and STS scores were
35.4, 16.3 and 14.6, respectively. The type of failure was stenosis/combined in 58% (mean
and peak aortic valve gradients 77 and 45 mmHg) and regurgitation 42% of cases. The
Sapien/XT® (Edwards Lifesciencies, Irvine, CA) and CoreValve® (Medtronic Inc,
Minneapolis, MN) system was used in 33 and 12 cases, respectively. The access routes
were transapical in 25, transfemoral in 17, transaortic in 2 and subclavian in one case. The
mean follow-up was 10.6 months. The periprocedural and postoperative outcome was
assessed according to the VARC criteria.
Results: There was no intraoperative mortality. The technical success rate was 95.6%
(one 2nd valve implantation, one conversion to open surgery). All-cause 30-day mortality
was 4.4% (one cardiac-related, one aspiration pneumonia). Major complications within 30
days were sroke in 2.2%, periprocedural MI in 4.4% and major vascular complication in
2.2% of patients. At 1 month all but one patient had either no or mild paravalvular leaks
with mean and peak valve gradients of 17(4-38) and 30(7-68) mmHg, respectively. The
mean gradient was  20 mmHg in 17% of patients; that remained unchanged at 12
months. The 1-year survival was 85.2%.
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